Additionally, the role of p66Shc in modulating survival pathways may have broader implications for NSC-like cancers, where assessing p66Shc levels could provide prognostic value for the sensitivity of cancers to EGFR- or MEK-inhibition-based chemotherapies. This evidence concerns the gene EGFR and cancer.